



December 25 2014

AnGes MG, Inc.

**AnGes Receives One-Off Payment from Mitsubishi Tanabe Pharma
For Exclusive Marketing Rights of HGF Plasmid in the United States**

AnGes MG, Inc. ("AnGes") announced that it has booked a one-off payment from Mitsubishi Tanabe Pharma Corporation (Head Office: Osaka, President & CEO, Masayuki Mitsuka, "MTPC") for the exclusive marketing rights of HGF Plasmid as a treatment for Peripheral Arterial Disease in the US as per contract concluded between the two parties on October 24, 2012.

Under the terms of the contract, AnGes is to receive a one-off payment, milestone payments based on development progress, and payments after product launch in accordance with the sales of HGF Plasmid in the US. AnGes and MTPC reached agreement on the initial payment, which AnGes recorded in the fourth quarter of 2014. Details of the payment and other financial terms of the contract are not disclosed.

Administration of the drug has already started in the US in the global Phase III clinical trial, which will examine the safety and efficacy of HGF Plasmid. The data will be collected for application to the US and European authorities.

AnGes will post the one-off payment as revenue for the fiscal year ending December 2014. The impact of this event has already been included in the forecast for 2014.

###

Disclaimer: This is a translation of the news release posted in Japanese. In case of any deviations between the two language versions, the original document in Japanese shall take precedence.

<p>AnGesMG, Inc. Corporate Communications TEL:+81-3-5730-2641, FAX:+81-3-5730-2635 http://www.anges-mg.com</p>
--